METX logo

ME Therapeutics Holdings CNSX:METX Stock Report

Last Price

CA$3.00

Market Cap

CA$70.9m

7D

-28.6%

1Y

185.7%

Updated

26 Dec, 2024

Data

Company Financials

ME Therapeutics Holdings Inc.

CNSX:METX Stock Report

Market Cap: CA$70.9m

METX Stock Overview

A preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. More details

METX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

ME Therapeutics Holdings Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for ME Therapeutics Holdings
Historical stock prices
Current Share PriceCA$3.00
52 Week HighCA$7.50
52 Week LowCA$0.75
Beta0
1 Month Change0%
3 Month Change-25.00%
1 Year Change185.71%
3 Year Changen/a
5 Year Changen/a
Change since IPO389.80%

Recent News & Updates

Recent updates

Shareholder Returns

METXCA BiotechsCA Market
7D-28.6%0.6%1.7%
1Y185.7%5.5%16.1%

Return vs Industry: METX exceeded the Canadian Biotechs industry which returned 5.5% over the past year.

Return vs Market: METX exceeded the Canadian Market which returned 16.1% over the past year.

Price Volatility

Is METX's price volatile compared to industry and market?
METX volatility
METX Average Weekly Movement30.0%
Biotechs Industry Average Movement13.7%
Market Average Movement8.1%
10% most volatile stocks in CA Market17.4%
10% least volatile stocks in CA Market3.0%

Stable Share Price: METX's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: METX's weekly volatility has decreased from 50% to 30% over the past year, but is still higher than 75% of Canadian stocks.

About the Company

FoundedEmployeesCEOWebsite
2014n/aSalim Dhanjiwww.metherapeutics.com

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations.

ME Therapeutics Holdings Inc. Fundamentals Summary

How do ME Therapeutics Holdings's earnings and revenue compare to its market cap?
METX fundamental statistics
Market capCA$70.90m
Earnings (TTM)CA$0
Revenue (TTM)n/a

n/a

P/E Ratio

n/a

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
METX income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$0
EarningsCA$0

Last Reported Earnings

n/a

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did METX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 13:06
End of Day Share Price 2024/12/23 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ME Therapeutics Holdings Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution